The knowledge gained could guide the design of trials aimed at demonstrating GLP-1 RA efficacy, particularly where a specific subgroup (eg, individuals with high cardiovascular risk or high levels of systemic inflammation or genetic risk for AD) is shown to be most likely to benefit from them. Here, GLP1R is linked to Alzheimer disease.